| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8597684 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US9675703 | TRIS PHARMA INC | Modified release formulations containing drug - ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8747902 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8883217 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US10086087 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(5 years from now) | |
| US11590228 | TRIS PHARMA INC | NA |
Sep, 2036
(12 years from now) | |
Dyanavel Xr is owned by Tris Pharma Inc.
Dyanavel Xr contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.
Dyanavel Xr has a total of 7 drug patents out of which 0 drug patents have expired.
Dyanavel Xr was authorised for market use on 19 October, 2015.
Dyanavel Xr is available in suspension, extended release;oral dosage forms.
Dyanavel Xr can be used as method of treating attention deficit hyperactivity disorder.
The generics of Dyanavel Xr are possible to be released after 07 September, 2036.
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
DYANAVEL XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic